全文获取类型
收费全文 | 3510篇 |
免费 | 320篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 122篇 |
妇产科学 | 42篇 |
基础医学 | 240篇 |
口腔科学 | 130篇 |
临床医学 | 253篇 |
内科学 | 519篇 |
皮肤病学 | 877篇 |
神经病学 | 78篇 |
特种医学 | 31篇 |
外科学 | 309篇 |
综合类 | 174篇 |
现状与发展 | 1篇 |
预防医学 | 24篇 |
眼科学 | 301篇 |
药学 | 565篇 |
中国医学 | 70篇 |
肿瘤学 | 55篇 |
出版年
2024年 | 2篇 |
2023年 | 79篇 |
2022年 | 59篇 |
2021年 | 150篇 |
2020年 | 164篇 |
2019年 | 174篇 |
2018年 | 182篇 |
2017年 | 136篇 |
2016年 | 162篇 |
2015年 | 109篇 |
2014年 | 145篇 |
2013年 | 446篇 |
2012年 | 120篇 |
2011年 | 158篇 |
2010年 | 119篇 |
2009年 | 136篇 |
2008年 | 148篇 |
2007年 | 119篇 |
2006年 | 134篇 |
2005年 | 130篇 |
2004年 | 118篇 |
2003年 | 89篇 |
2002年 | 86篇 |
2001年 | 68篇 |
2000年 | 63篇 |
1999年 | 57篇 |
1998年 | 43篇 |
1997年 | 43篇 |
1996年 | 38篇 |
1995年 | 41篇 |
1994年 | 41篇 |
1993年 | 26篇 |
1992年 | 36篇 |
1991年 | 25篇 |
1990年 | 24篇 |
1989年 | 27篇 |
1988年 | 24篇 |
1987年 | 23篇 |
1986年 | 15篇 |
1985年 | 20篇 |
1984年 | 14篇 |
1983年 | 12篇 |
1982年 | 15篇 |
1981年 | 4篇 |
1980年 | 9篇 |
1979年 | 3篇 |
1978年 | 5篇 |
1976年 | 5篇 |
1975年 | 6篇 |
1974年 | 5篇 |
排序方式: 共有3859条查询结果,搜索用时 171 毫秒
11.
J. MULLOL E. LÓPEZ J. ROCA-FERRER A. XAUBET L. PUJOLS J. C. FERNÀNDEZ-MORATA J. M. FABRA† C. PICADO 《Clinical and experimental allergy》1997,27(12):1432-1441
Background Eosinophil infiltration is a hallmark of the inflammatory response in rhinitis and in nasal polypcsis. Objective We studied the effect of steroids and nedocromil sodium on eosinophil survival primed by epithelial cells from healthy (nasal mucosa) and inflamed (nasal polyp) respiratory tissue. Methods Blood eosinophils were incubated with increasing concentrations (10-11 10-5 M) of topical steroids (fiuticasone propionate, budesonide, triamcinolone acetonide and beclomethasone dipropionate) and/or nedocromil sodium prior to the addition of human epithelial cell conditioned media (HECM), eosinophil viability was measured and IC50 for each drug was calculated. Results All four steroids and nedocromil sodium caused a dose-related inhibition of HECM-induced eosinophil survival. The IC50 of steroids were lower in eosinophils primed by mucosa HECM than on those primed by polyp HECM (fluticasone, 4nM vs 114nM: budesonide, 21 nM vs 280 nM; triamcinolone, 7 nM vs 853 nM; and beclomethasone, 171 nM vs 181 nM). The combined inhibitory effect of 10-7M budesonide plus 10-5M nedocromil (43.8 ± 10.8%, P < 0.03) was significantly higher than budesonide (28.5 ± 9.2%) or nedocromil (16.7 ± 5.4%) alone and close to 10-5M budesonide (52.3 ± 11%). No differences were found in cytokine (IL-8, IL-6, GM-CSF, TNFα, IL-lβ and RANTES) concentrations between HECM from mucosa and polyps. Conclusion These results suggest that topical anti-inflammatory drugs may diminish airway eosinophilic infiltration by decreasing eosinophil viability, that nasal polyp epithelial cell secretions may induce steroid resistance in eosinophils, and that nedocromil sodium has additive effects with steroids. 相似文献
12.
Ten patients with bilateral moderate or severe otitis externa were studied. Following aural toilet each patient was subjected to two different treatments: one ear had alternate day dressings containing a topical antibiotic/steroid mixture, while the external canal of the other was filled with the same topical preparation (sump filling). Improvement in the severity of the otitis externa was assessed after 1 week. 9 out of 10 ear canals improved in each group. An estimate of the relative cost of each treatment was made and sump filling was found to be less expensive. The results suggest that sump filling is a low cost alternative to standard treatment in moderate and severe otitis externa. 相似文献
13.
肝素钠软膏(海普林)治疗皮质类固醇激素依赖性皮炎疗效观察 总被引:3,自引:0,他引:3
目的观察肝素钠软膏(海普林)治疗皮质类固醇激素依赖性皮炎的效果。方法随机抽取部分病例组成对照组,其余病例组成治疗组,分别使用单纯乳剂和肝素钠软膏外涂,配合相关内服药物治疗,比较治疗组和对照组疗效。结果对照组治疗有效率为24.81%,治疗组治疗有效率为52.24%,两组结果差异有非常显著性。结论应用肝素钠软膏外用治疗皮质类固醇激素依赖性皮炎取得了满意的疗效。 相似文献
14.
Cross-reactions in topical corticosteroid contact dermatitis 总被引:3,自引:0,他引:3
15.
Systemic contact dermatitis from erythromycin 总被引:1,自引:0,他引:1
16.
C. J. Corrigan R. J. Shiner† B. H. Shakur† P. W. Ind† 《Clinical and experimental allergy》2005,35(5):579-584
BACKGROUND: Concomitant methotrexate (MTX) therapy of oral corticosteroid (CS)-dependent asthmatics has been shown to spare CS therapy, but the mechanism is unknown. In a previous report, we showed that MTX increases T cell inhibition by CS. In this report we focus on effects of MTX on immunoglobulin concentrations and their possible clinical relevance. OBJECTIVE: To monitor changes in circulating leucocytes and Ig in a group of these patients during MTX therapy, and to relate these changes to clinical 'response' as defined by oral CS reduction. METHODS: Sixteen severe asthmatics dependent on oral prednisolone 15 (7.5-25) mg/day in addition to high dose inhaled CS were treated with MTX 15 mg intramuscularly, weekly for 28 weeks. Prednisolone dosages were maintained constant for 12 weeks then reduced systematically over the next 16 weeks provided that asthma control did not deteriorate. Patients were classified a priori as 'responders' or 'non-responders' to MTX (reduction of initial oral prednisolone requirement by >or=50% or <50%, respectively). Patients were followed-up for a further 12 weeks after MTX withdrawal. Serum Ig and differential blood leucocyte counts were measured at baseline, 12, 28 and 40 weeks. RESULTS: MTX therapy allowed significant, but individually variable, reductions in oral prednisolone dosages (P<0.00001) without alteration of lung function or symptoms. This was associated with significant reductions in mean serum concentrations of Ig of all classes, which reversed following MTX withdrawal. Reductions in IgE and IgG were significantly greater in the MTX 'responders' as compared with 'non-responders', and changes in IgE, IgG and IgM correlated with changes in prednisolone requirements. Differential blood leucocyte counts showed no significant variation. CONCLUSION: MTX therapy reduced oral CS requirements in these severe asthmatics to a degree which correlated with reduced circulating Ig but not lymphopaenia, suggesting a possible cause and effect relationship. These reductions might also contribute to the documented incidence of opportunistic infection in these circumstances. 相似文献
17.
Peter MA Calverley Romain A Pauwels Paul W Jones Julie A Anderson J?rgen Vestbo 《INT J CHRONIC OBSTR》2006,1(3):209-218
Guidelines recommend that patients with COPD are stratified arbitrarily by baseline severity (FEV1) to decide when to initiate combination treatment with a long-acting β2-agonist and an inhaled corticosteroid. Assessment of baseline FEV1 as a continuous variable may provide a more reliable prediction of treatment effects. Patients from a 1-year, parallel-group, randomized controlled trial comparing 50 μg salmeterol (Sal), 500 μg fluticasone propionate (FP), the combination (Sal/FP) and placebo, (bid), were categorized post hoc into FEV1 <50% and FEV1 ≥50% predicted subgroups (n=949/513 respectively). Treatment effects on clinical outcomes – lung function, exacerbations, health status, diary card symptoms, and adverse events – were investigated. Treatment responses based on a pre-specified analysis explored treatment differences by severity as a continuous variable. Lung function improved with active treatment irrespective of FEV1; Sal/FP had greatest effect. This improvement appeared additive in milder disease; synergistic in severe disease. Active therapy significantly reduced exacerbation rate in patients with FEV1 <50% predicted, not in milder disease. Health status and breathlessness improved with Sal/FP irrespective of baseline FEV1; adverse events were similar across subgroups. The spirometric response to Sal/FP varied with baseline FEV1, and clinical benefits were not restricted to patients with severe disease. These data have implications for COPD management decisions, suggesting that arbitrary stratifications of baseline severity are not necessarily indicative of treatment efficacy and that the benefits of assessing baseline severity as a continuous variable should be assessed in future trials. 相似文献
18.
The effectiveness of intranasal corticosteroids in combined allergic rhinitis and asthma syndrome 总被引:2,自引:0,他引:2
Background Allergic rhinitis (AR) and asthma often coexist and may represent two manifestations of the same disease recently named combined AR and asthma syndrome (CARAS). Aim To review the common pathophysiology of combined AR and asthma and to investigate the efficacy of intranasal corticosteroids (INCS). Methods Medline was used to identify articles relevant to mechanisms. A Cochrane systematic review was performed to assess the efficacy of INCS in CARAS. Results There is cross‐talk, evidence of a common inflammatory response in both sites, linked by a systemic component. The efficacy of anti‐inflammatory INCS on asthma outcomes was assessed in a systematic review of 12 randomized controlled trials involving 425 subjects. After INCS there were non‐significant trends for improvement in asthma symptom score (standardized mean difference (SMD) of 0.61; P=0.07), forced expiratory volume in 1 s (SMD of 0.31; P=0.08), and morning peak expiratory flow (weighted mean difference of 36.51; P=0.06). There was no impact on methacholine airways responsiveness (SMD of ?0.20; P=0.4). The review identified two promising new treatment options in united airway disease such as INCS as monotherapy in rhinitis and mild asthma, and a combined intranasal and intrabronchial corticosteroid (IBCS) deposition technique. Conclusion Common mucosal inflammatory responses occur in CARAS. This systematic review shows trends for a benefit of INCS in CARAS, but recognizes that more research is needed. At this stage, the current best practice is to treat asthma conventionally with IBCS with or without β2‐agonist and to add INCS to improve specific rhinitis symptoms. 相似文献
19.
Tobias Forschner Stefan Buchholtz Eggert Stockfleth 《Journal der Deutschen Dermatologischen Gesellschaft》2007,5(6):467-475
Vitiligo is a skin disease with a worldwide prevalence ranging from 0.5% to 4%. Conservative therapies include photochemotherapy, phototherapy with UVB radiation (broadband UVB 290–320 nm, narrow band UVB 311 nm), systemic steroids and pseudocatalase. Modern therapeutic options include treatment with topical immunomodulators (tacrolimus, pimecrolimus), analogues of vitamin D3, excimer laser and surgery/transplantation. Our analysis compares these therapies for vitiligo and the evidence levels supporting their effectiveness. Conclusions: The face and neck respond best to all therapeutic approaches, while the acral areas are least responsive. For generalized vitiligo, phototherapy with UVB radiation is most effective with the fewest side effects; PUVA is the second best choice.Topical corticosteroids are the preferred drugs for localized vitiligo. They may be replaced by topical immunomodulators which display comparable effectiveness and fewer side effects.The effectiveness of vitamin D analogues is controversial with limited data. Surgical therapy can be very successful, but requires an experienced surgeon and is very demanding of time and facilities, thus limiting its widespread use. L-phenylalanine therapy appears effective on the face but enjoys neither widespread use nor extensive data support. No single therapy for vitiligo can be regarded as the most effective as the success of each treatment modality depends on the type and location of vitiligo. 相似文献
20.